The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

28 Apr 2017 15:37

RNS Number : 7478D
Mereo BioPharma Group plc
28 April 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Mereo BioPharma Group plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Novartis Pharma AG

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

27 April 2017

6. Date on which issuer notified:

27 April 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

19%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary shares

of £0.03 each

 

GB00BZ4G2K23

12,546,480

18.1%

13,767,841

19.5%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

13,767,841

19.5%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Marc Ceulemans

15. Contact telephone number:

00 41 61 324 5365

 

Note: Annex should only be submitted to the FCA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

Contact address

(registered office for legal entities)

 

Phone number & email

 

Other useful information

(at least legal representative for legal persons)

 

B: Identity of the notifier, if applicable

Full name

 

Contact address

 

Phone number & email

 

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

For notes on how to complete form TR-1 please see the FCA website.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLIPMITMBJTBIR
Date   Source Headline
10th Sep 20191:00 pmRNSNotice of Results
6th Sep 20197:00 amRNSBlock listing Interim Review
4th Sep 20191:00 pmRNSMereo announces phase 2b data at ASBMR Meeting
16th Aug 20191:51 pmRNSDirector/PDMR Shareholding
15th Aug 20194:59 pmRNSPDMR Shareholding
12th Aug 20194:41 pmRNSSecond Price Monitoring Extn
12th Aug 20194:35 pmRNSPrice Monitoring Extension
9th Aug 20194:35 pmRNSPrice Monitoring Extension
31st Jul 201912:51 pmRNSDirector Declaration
25th Jul 20194:56 pmRNSPDMR Shareholding
24th Jul 201910:08 amRNSDirector/PDMR Shareholding
19th Jul 20191:21 pmRNSDirector/PDMR Shareholding
16th Jul 20191:00 pmRNSAppointment of Richard Francis
15th Jul 20191:00 pmRNSSuccessful Type B Meeting with U.S. FDA
8th Jul 20193:54 pmRNSHolding(s) in Company
3rd Jul 20194:41 pmRNSSecond Price Monitoring Extn
3rd Jul 20194:35 pmRNSPrice Monitoring Extension
27th Jun 20193:33 pmRNSHolding(s) in Company
26th Jun 20194:36 pmRNSHolding(s) in Company
21st Jun 20191:00 pmRNSConversion of loan note and issue of equity
20th Jun 20197:00 amRNSResult of AGM
13th Jun 20191:00 pmRNSUpdate on Etigilimab (TIGIT) Partnership
30th May 20197:00 amRNSPositive early 6 month data
23rd May 20194:11 pmRNSDirector/PDMR Shareholding
22nd May 20199:45 amRNSPDMR Shareholding
21st May 20193:08 pmRNSDirector/PDMR Shareholding
20th May 20197:00 amRNSNotice of AGM
8th May 20191:53 pmRNSDirector/PDMR Shareholding
7th May 20197:00 amRNSIssue of Warrants
7th May 20197:00 amRNSRe-release: Intention to Purchase Shares
3rd May 20195:00 pmRNSIntention to Purchase Shares by Trustee of EBT
3rd May 20192:02 pmRNSDirector/PDMR Shareholding
1st May 20193:47 pmRNSDirector/PDMR Shareholding
30th Apr 20193:15 pmRNSDirector/PDMR Shareholding
30th Apr 20197:00 amRNSDirector/PDMR Shareholding
30th Apr 20197:00 amRNSPublication of Annual Report and Accounts
29th Apr 20197:00 amRNSPrelims Results for year ended December 31 2018
26th Apr 20193:01 pmRNSDirector/PDMR Shareholding
25th Apr 20193:36 pmRNSHolding(s) in Company
25th Apr 20193:29 pmRNSHolding(s) in Company
24th Apr 20192:30 pmRNSAdmission to Trading
23rd Apr 20192:25 pmRNSCompletion of Merger
18th Apr 20197:00 amRNSMerger Update
15th Apr 20197:00 amRNSSuccessful end of Phase 2 Meeting with FDA
21st Mar 20197:00 amRNSPublication of Form F-4
15th Mar 201911:45 amRNSUpdate on Proposed Combination of Mereo & OncoMed
13th Mar 201911:00 amRNSMereo CEO appointed NED of Elanco Animal Health
6th Mar 20197:00 amRNSBlock Listing Interim Review
5th Mar 20191:32 pmRNSMereo to present at Cowen and Company Conference
22nd Feb 20191:50 pmRNSUpdate on Proposed Transaction with OncoMed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.